By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

Breast cancer is a heterogeneous malignancy that can be divided into several molecular subtypes according to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 ...

HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer cells with estrogen or progesterone hormone receptors can grow in response ...

Progesterone is involved in regulating the female menstrual cycle. Hormone receptor-positive breast cancer is fueled by estrogen and progesterone, while triple-negative breast cancer cells are not ...

Triple-positive breast cancer is a type of breast cancer that tests positive for estrogen receptors, progesterone receptors, and high levels of HER2 protein. Some types of breast cancer cells use ...

Development of a highly sensitive in vitro system to detect and discriminate between vitamin D receptor agonists and antagonists based on split-luciferase technique.

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

The weak positive progesterone receptor (PR) expressed in this case is extremely rare, which may provide a new research direction for the endocrine therapy of AcCC. Both AcCC and microglandular ...